EUVIMEDEUVIMED entdecken
Crossref

PD-L1-Targeted and ROS-Responsive Nanoplatform for Simultaneous Chemotherapy and Dual-Modal Imaging of Treatment Response in Triple-Negative Breast Cancer

Jingjing Hu, Chunting Wang, Yanhong Chen, Cuiying Zhu, Aoyu Liu, Dian Chen, Ling Zhan, Defan Yao iD, Dengbin Wang iD

ACS Sensors · 2026

DOI: 10.1021/acssensors.6c03428 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Sensors, 2026. Verfasst von Jingjing Hu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai200092, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Doxorubicin, Reactive Oxygen Species, B7-H1 Antigen. Die Arbeit nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality, Shanghai Leading Academic Discipline Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The evaluation of treatment response in triple-negative breast cancer (TNBC) still primarily relies on tumor size and ex vivo analyses, which provide very limited information on how tumors dynamically respond during therapy. In fact, oxidative stress rapidly emerges early after drug treatment, while PD-L1 reflects an adaptive signal associated with tumors. However, these treatment-associated features are commonly assessed using static detection methods, thereby limiting longitudinal in vivo evaluation. To address this, we developed a theranostic nanoprobe named RAPP, which integrates DOX delivery, ROS-responsive near-infrared fluorescence (NIRF) imaging, and PD-L1-targeted magnetic resonance imaging (MRI). In this system, the fluorescence signal serves to report early oxidative stress in real time, while PD-L1 targeting contributes to tumor-directed MRI, enabling longitudinal assessment of both signals in a 4T1 TNBC model. During treatment, RAPP produced distinct changes in fluorescence and MR signals across different experimental groups, indicating the complementarity of these two imaging modalities in evaluating tumor response. Furthermore, DOX-loaded RAPP effectively inhibited tumor growth without exhibiting significant systemic toxicity. By integrating drug delivery with dual-modal imaging, RAPP offers a practical strategy for assessing tumor response in TNBC during treatment, rather than only after treatment completion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsDoxorubicinReactive Oxygen SpeciesB7-H1 AntigenNanoparticlesAntineoplastic AgentsAnimalsFemaleMagnetic Resonance ImagingHumansMiceOptical ImagingCell Line, TumorMice, Inbred BALB C

Stichwörter der Autor:innen

PD-L1 targetingROS-responsivedual-modal imagingoxidative stresstheranostic nanoprobestriple-negative breast cancer

Substanzen

DoxorubicinReactive Oxygen SpeciesB7-H1 AntigenCD274 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Radiology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai200092, China.
  • Faculty of Medical Imaging Technology, College of Health Science and Technology, Shanghai Jiao Tong University School of Medicine, Shanghai200025, China.
  • Shanghai University of Sport , Shanghai200438, China.

ORCID-Profile: Defan Yao, Dengbin Wang

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Commission of Shanghai Municipality
  • Shanghai Leading Academic Discipline Project

Zitieren

APA

Hu, J., Wang, C., Chen, Y., Zhu, C., Liu, A., Chen, D., Zhan, L., Yao, D., & Wang, D. (2026). PD-L1-Targeted and ROS-Responsive Nanoplatform for Simultaneous Chemotherapy and Dual-Modal Imaging of Treatment Response in Triple-Negative Breast Cancer. ACS Sensors. https://doi.org/10.1021/acssensors.6c03428

Vancouver

Hu J, Wang C, Chen Y, Zhu C, Liu A, Chen D, et al. PD-L1-Targeted and ROS-Responsive Nanoplatform for Simultaneous Chemotherapy and Dual-Modal Imaging of Treatment Response in Triple-Negative Breast Cancer. ACS Sensors. 2026. doi:10.1021/acssensors.6c03428

BibTeX
@article{Hu2026,
  author = {Hu, Jingjing and Wang, Chunting and Chen, Yanhong and Zhu, Cuiying and Liu, Aoyu and Chen, Dian and Zhan, Ling and Yao, Defan and Wang, Dengbin},
  title = {PD-L1-Targeted and ROS-Responsive Nanoplatform for Simultaneous Chemotherapy and Dual-Modal Imaging of Treatment Response in Triple-Negative Breast Cancer},
  journal = {ACS Sensors},
  year = {2026},
  doi = {10.1021/acssensors.6c03428}
}
Kostenlos starten →